Publicaciones en colaboración con investigadores/as de Curtin University (29)

2023

  1. A deep learning system for detection of early Barrett's neoplasia: a model development and validation study

    The Lancet Digital Health, Vol. 5, Núm. 12, pp. e905-e916

  2. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

    Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197

  3. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

    Breast, Vol. 67, pp. 94-101

  4. Impact of Post-PCI FFR Stratified by Coronary Artery

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 19, pp. 2396-2408

  5. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

    European Journal of Cancer, Vol. 184, pp. 48-59

  6. Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) – Proceedings from the SOGLI consortium meeting in rome November 2022

    Clinical Nutrition

2022

  1. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293

  2. Code of practice needed for samples donated by trial participants

    The Lancet Oncology

  3. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study

    British Journal of Sports Medicine, Vol. 56, Núm. 20, pp. 1157-1170

2021

  1. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

    Clinical Breast Cancer, Vol. 21, Núm. 1, pp. 80-91.e7

2020

  1. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 60-72

  2. Age and APOE genotype affect the relationship between objectively measured physical activity and power in the alpha band, a marker of brain disease

    Alzheimer's Research and Therapy, Vol. 12, Núm. 1

  3. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

  4. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

    Scientific reports, Vol. 10, Núm. 1, pp. 9688

  5. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1223-1230

  6. The relationship between physical activity, apolipoprotein e ϵ4 carriage, and brain health

    Alzheimer's Research and Therapy, Vol. 12, Núm. 1

  7. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

    Genetic Epidemiology, Vol. 44, Núm. 5, pp. 442-468

2019

  1. Change in Blood Pressure Variability Among Treated Elderly Hypertensive Patients and Its Association With Mortality

    Journal of the American Heart Association, Vol. 8, Núm. 21

  2. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: Longitudinal analyses from the randomized phase III ExteNET trial

    Annals of Oncology, Vol. 30, Núm. 4, pp. 567-574

  3. PIK3CA alterations and benefit with neratinib: Analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

    Breast Cancer Research, Vol. 21, Núm. 1